Stoke Therapeutics, Inc. (STOK) Tops Q1 EPS by 5c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q1 EPS of ($0.57), $0.05 better than the analyst estimate of ($0.62). Revenue for the quarter came in at $4.2 million versus the consensus estimate of $3.21 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• Nordson Corp. (NDSN) Tops Q3 EPS by 16c; Offers Guidance
• Jaguar Health (JAGX) Tops Q2 EPS by 3647c
• Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)